Skip to content

Quick ratio at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.8×-0.3×
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
32.6×+16.8×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.4×+4.3×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
17.8×+0.5×
Summit Therapeutics logo
Summit TherapeuticsSMMT
7.4×-3.2×
TG Therapeutics logo
TG TherapeuticsTGTX
5.7×+2.6×

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Calculated from Immunovant, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s quick ratio?
Immunovant, Inc. (IMVT) reported quick ratio of 9.1× in Q1 2026.
How has Immunovant, Inc.'s quick ratio changed year-over-year?
Immunovant, Inc.'s quick ratio decreased by 18.6% year-over-year, from 11.2× to 9.1×.
What is the long-term trend for Immunovant, Inc.'s quick ratio?
Over 5 years (2021 to 2026), Immunovant, Inc.'s quick ratio has grown at a -16.0% compound annual growth rate (CAGR), from 21.8× to 9.1×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.